MarketPulse

phase 2b

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Kymera Therapeutics Advances IBD Pipeline With Promising KT-579 Preclinical Data

Kymera Therapeutics showcases KT-579 preclinical data matching approved IBD therapies ahead of Phase 1 trials in late 2026.
KYMRclinical trialinflammatory bowel disease
GlobeNewswire Inc.GlobeNewswire Inc.··Radiopharm Theranostics

Radiopharm Theranostics Advances Pipeline as Cash Dwindles to $19.2M

Radiopharm completes Phase 2b enrollment for brain imaging agent RAD 101 with 90% MRI concordance, initiates new trials while cash reserves fall sharply.
RADXclinical trialsradiopharmaceuticals
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Lexicon Advances Pain Drug After Positive Phase 2b Results

Lexicon Pharmaceuticals' pilavapadin shows promise in diabetic neuropathic pain study, supporting 10mg dose selection for Phase 3 trials.
LXRXclinical trialPhase 3
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Duvakitug Shows Sustained Remission in Phase 2b Trial for Inflammatory Bowel Disease

Teva and Sanofi's duvakitug showed sustained remission in phase 2b trial for inflammatory bowel disease, with remission rates of 41-58% depending on condition and dosage.
SNYTEVAmonoclonal antibodyinflammatory bowel disease
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Teva

Sanofi, Teva Report Sustained Efficacy for TL1A Inhibitor in IBD Phase 2b Trial

Sanofi and Teva's duvakitug showed sustained efficacy treating ulcerative colitis and Crohn's disease in a Phase 2b trial, supporting advancement to Phase 3 development.
SNYTEVAmonoclonal antibodyinflammatory bowel disease